




MDH-032 for the Treatment of Intractable Metabolic Disease

MDH-032 (*Lactobacillus rhamnosus* EV) is a new class of first-in-class oral otherapeutic indicated for intractable metabolic diseases, such as non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and more

MDH-032

- Naïve (natural) EVs from a single **Lactobacillus** strain



Value Propositions

1. **First-in-class:** a new modality drug with a novel mechanism of action (MoA)
2. **Very safe:** a safe commensal bacterium *Lactobacillus rhamnosus*-derived EVs
3. **Effective:** a disease-modifying therapy against intractable metabolic diseases, including non-alcoholic steatohepatitis (NASH) and chronic kidney disease (CKD)
4. **Convenient administration:** orally-delivered
5. **Affordable:** cost effective production

MDH-032: Key Indications & Development Timeline

Key Indications

- 1) Non-alcoholic steatohepatitis (NASH)**
- 2) Chronic kidney disease (CKD)**
- 3) Idiopathic pulmonary fibrosis (IPF)**
- 4) Liver cirrhosis (LC)
- 5) Diabetic nephropathy

Core patents

1. Core patent (1)
 - ✓ PCT application date at 05/Mar/2019
 - ✓ Registered at KR (as of July 2022)
2. Core patent (2)
 - ✓ PCT application date at 31/May/2022

Development Timeline

IND filing ('24)



P1 ('25)



P2 ('27)



Exit